Introduction
============

Lung cancer is one of the leading causes of death worldwide, is closely associated with lung disease, and its incidence continues to rise [@B1]-[@B5]. The 5-year survival rate remains at 15% and the prognosis of non-small cell lung cancer (NSCLC) patients is mainly related to tumor metastasis, which is related to transcriptional regulation of some key genes [@B5], [@B6]-[@B8]. Therefore, understanding the mechanism of NSCLC progression is very important for the treatment of NSCLC.

The Notch pathway is involved in development and cell proliferation, differentiation, and apoptosis. As a result of its multiple effects on tissue homeostasis and cancer, this signaling pathway has attracted increasing attention as a potential therapeutic target. Notch proteins belong to a highly conserved family of cell surface receptors. Ligand binding leads to the complex proteolysis of these receptors by the γ-secretase complex, followed by translocation of the active intracellular incision nuclei and transcriptional activation domains [@B9]. Notch signaling is activated by a ligand that binds to a receptor, initiating an intercellular communication system of five ligands (Delta-like 1, Delta-like 3, Delta-like 4, Jagged-1, and Jagged-2) and four receptors (Notch1-4). Ligand binding causes conformational changes of Notch, resulting in the exposure of the S2 site and sequence cleavage by the protease, disintegrase, a member of the metalloproteinase family and gamma secretase complex, to release the Notch intracellular domain (NICD). Finally, NICD is transferred to the nucleus, where it induces the target gene [@B10], [@B11] Yitong et al. 2018).

Tripartite motif-containing (TRIM) proteins are characterized by a common domain consisting of a RING finger, one or two B-box motifs and a coiled-coil motif, and are involved in many biological processes, including innate immunity, viral infection, cancer, and development [@B12]-[@B14]. TRIM67 belongs to the tripartite motif (TRIM) protein family [@B15]. Therefore, TRIM67 may be a specific E3 ubiquitin ligase, which is significant for target protein ubiquitin-dependent degradation or stabilization [@B16]. TRIM67 was reported to be associated with the nervous system [@B17]-[@B19], but its function in tumors has not been reported.

In this study, we demonstrated that TRIM67 promotes the proliferation, migration, invasion and EMT of NSCLC cells through the Notch pathway. Additionally, we detected the expression of TRIM67 in NSCLC tissues and cell lines by immunohistochemistry and western blotting and altered the expression of TRIM67 in NSCLC cells to study the variations of the cancer-related phenotype and determine its role in NSCLC.

Methods
=======

Specimens and patient data
--------------------------

These assays were performed as described previously [@B5]. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards, and informed consent was obtained from all individual participants.

Immunohistochemistry
--------------------

These assays were performed as described previously [@B5].

Cell culture
------------

These assays were performed as described previously [@B5].

Plasmid construction, transfection, and administration of Notch pathway inhibitors
----------------------------------------------------------------------------------

According to the manufacturer\'s instructions, Lipofectamine 3000 reagent was largely used for cell transfection (Invitrogen, Carlsbad, CA, USA). We used short hairpin RNA (shRNA) targeting *TRIM67* to knockdown the expression of *TRIM67*, which was cloned into the SGU6 vector (Sangon Biotech, Shanghai), for 48 h. For upregulating the expression of *TRIM67*, we used *TRIM67*-expression plasmid and the corresponding empty pCMVNeo04 vector (LongqianBiotech, Shanghai, China).

To inhibit Notch signaling, we treated cells with 4 µM DAPT (MedChemExpress, Monmouth Junction, NJ, USA), a γ-secretase inhibitor blocking the Notch pathway, in dimethyl sulfoxide (DMSO), and an equal amount of DMSO was accordingly supplied to cells as a control 24 h after transfection.

Immunocytochemistry
-------------------

Lung cancer cells cultured in 24-well plates for 24 h were immobilized in paraformaldehyde (4%) for 15 min and permeated with 0.1% Triton X-100 for 10 min. Next, the cells were washed with PBS and then blocked in bovine serum albumin (5%) for 1 h and incubated with anti-TRIM67 antibody (1:50) at 4 °C overnight. Thereafter, the cells were incubated with the secondary antibody, TRITC binding antibody, for 2 h; cell nuclei were re-stained with DAPI, and images were captured using the Olympus FV1000 laser scanning confocal microscope (Olympus, Tokyo, Japan).

Western blotting
----------------

Western blotting revealed several functional proteins that directly affect cell migration, cell invasion [@B28]-[@B30], and cell proliferation [@B31], [@B32]. Cellular proteins were extracted using lysis buffer (P0013; Beyotime Biosciences, Shanghai, China) containing protease-inhibitor cocktail (B14002; Biotool, Shanghai, China). Proteins were quantified using the Bradford method. Approximately 60 µg of each protein was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis on 10% gels, transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA), blocked in 5% skim milk (232100; Becton Dickenson, Franklin Lakes, NJ, USA) at 28 ºC, and incubated with antibodies (Table [1](#T1){ref-type="table"}) overnight at 4 ºC. Membranes were then washed and incubated with horseradish peroxidase-conjugated anti-mouse/rabbit IgG (1:2000; ZSGB-BIO, Beijing, China) at 37 ºC for 2 h. Finally, immunoreactivity was detected using the BioImaging system (UVP, Inc., Upland, CA, USA).

Cell migration and invasion analyses
------------------------------------

These assays were performed as described previously [@B5].

Cell proliferation and colony formation assays
----------------------------------------------

These assays were performed as described previously [@B33].

Statistical analysis
--------------------

Statistical analyses were mostly performed using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). Survival rates were analyzed by the Kaplan-Meier method and compared by the log rank test (Kaplan-Meier Plotter. Available from URL: <http://www.kmplot.com/analysis/index.php?p=service&cancer=lung>) [@B34]^.^ Student\'s t-test was used to analyze statistically significant differences between the expression of TRIM67 and clinical features, and P \< 0.05 was considered statistically significant.

Results
=======

*TRIM67* correlates with clinicopathological characteristics and poor prognosis
-------------------------------------------------------------------------------

Immunofluorescence analysis of seven NSCLC cells showed that TRIM67 was localized in both the cytoplasm and nucleus (Fig. [1](#F1){ref-type="fig"}c). Moreover, immunohistochemical analysis showed that TRIM67 expression in low-differentiated NSCLC tissues was significantly higher than that in high-differentiated NSCLC tissues (Fig. [1](#F1){ref-type="fig"}a). Next, we investigated whether TRIM67 protein levels were associated with clinical features. The results showed that TRIM67 levels were positively correlated with differentiation (P \< 0.001), tumor size (P = 0.018), lymph node metastasis (P \< 0.001), and pathological TNM stage (P \< 0.001), but not age (P = 0.424), sex (P = 0.328), and histological type (P = 0.514) as shown in Table [2](#T2){ref-type="table"}. Moreover, high expression of TRIM67 was associated with lower survival in NSCLC patients according to the Kaplan-Meier database (Fig. [1](#F1){ref-type="fig"}b). Based on the above results, we suggest that TRIM67 might have an important effect on the biological functions of NSCLC.

Western blot analysis was also performed to determine the expression of TRIM67 in HBE normal bronchial epithelial cells and six NSCLC cell lines (Fig. [1](#F1){ref-type="fig"}d), and then we selected A549 and H1299 cell lines for subsequent studies because TRIM67 was moderately expressed in these two cell lines.

TRIM67 expression promotes migration and invasion of NSCLC cells
----------------------------------------------------------------

Based on the previously mentioned findings, we next studied the effect of TRIM67 protein in NSCLC. To this end, we altered TRIM67 expression by downregulation or upregulation in both A549 and H1299 cell lines. We found that TRIM67 knockdown inhibited the migration and invasion of A549 and H1299 cells as compared to that of control cells through Transwell assays, whereas migration and invasion were promoted by TRIM67 overexpression (P \< 0.05; Fig. [2](#F2){ref-type="fig"}a). Further, alteration of TRIM67 protein expression had an effect on the expression of proteins related to cell migration and invasion, consistent with the aforementioned results. Transfection efficiency was also examined by western blotting 48 h post-transfection. Upon TRIM67 upregulation, the levels of RhoA, RhoC, and matrix metalloproteinase (MMP)-9 increased, whereas its downregulation exerted the opposite effect (Fig. [2](#F2){ref-type="fig"}b and c). Consistent with our immunohistochemical results, these results suggested that TRIM67 enhances the migration and invasion of NSCLC cells.

TRIM67 expression promotes the proliferation of NSCLC cells
-----------------------------------------------------------

We next analyzed the effect of TRIM67 expression on cell proliferation. Colony formation analysis clearly demonstrated that TRIM67 expression and colony-formation ability of tumor cells were positively correlated in A549 and H1299 cells; specifically, downregulation inhibited clone formation, whereas upregulation had the opposite effect, when compared to that in respective control groups (Fig. [3](#F3){ref-type="fig"}a). Subsequent MTT assays revealed that upregulation of TRIM67 expression enhanced cell proliferation, whereas downregulation had an opposite effect in A549 cells (Fig. [3](#F3){ref-type="fig"}b), similar to the observation in H1299 cells (Fig. [3](#F3){ref-type="fig"}c). Consistent with these observations, TRIM67 overexpression promoted the proliferation of NSCLC cells, which also agreed with our immunohistochemical results showing that TRIM67 levels are associated with tumor size. We next analyzed the proliferation-related proteins, and the results showed that when TRIM67 was upregulated, the expression of c-Myc was also upregulated, whereas that of P21 was downregulated; knockdown of TRIM67 had the opposite effect on these proteins in both A549 and H1299 cells (Fig. [3](#F3){ref-type="fig"}d and e).

TRIM67 positively regulates the expression of proteins related to epithelial-mesenchymal transition (EMT)
---------------------------------------------------------------------------------------------------------

To elucidate the mechanism by which TRIM67 enhances the migration/invasion of lung cancer cells, we detected the expression of EMT-related proteins by western blotting. Results showed that increased TRIM67 expression enhanced N-cadherin, vimentin, Snail, and slug expression, but suppressed E-cadherin in A549 cells (Fig. [4](#F4){ref-type="fig"}a), similar to the observation in H1299 cells (Fig. [4](#F4){ref-type="fig"}b). These results revealed that TRIM67 can affect the migration and invasion of NSCLC cells by promoting epithelial-mesenchymal transition(EMT).

TRIM67 regulates migration, invasion, cell proliferation, and EMT of NSCLC cells through the Notch pathway
----------------------------------------------------------------------------------------------------------

We clarified the role of TRIM67 in NSCLC cell migration, invasion, and proliferation and then investigated the biological mechanisms related to these effects. The Notch pathway is involved in the development of several cancers by influencing the expression of EMT-related proteins and other factors found to be altered by TRIM67 modulation; therefore, we examined whether TRIM67 is involved in the regulation of Notch signaling in NSCLC cells. Western blotting results showed that TRIM67 knockdown downregulated the expression of Notch1, Jagged1, and NICD in A549 and H1299 cell lines, whereas overexpression had the opposite effects (Fig. [5](#F5){ref-type="fig"}a and b). To investigate whether the function of TRIM67 was mediated through the Notch pathway, we used the inhibitor, DAPT, which inhibits NICD expression. DAPT inhibited cell migration, invasion, and proliferation in A549 and H1299 cells transfected with p-trim67 (Fig. [5](#F5){ref-type="fig"}c and [6](#F6){ref-type="fig"}a), and the effect of TRIM67 overexpression on protein expression of A549 and H1299 cells was reversed (Fig. [6](#F6){ref-type="fig"}b and c). These results indicated that activation of the Notch pathway contributes to TRIM67-mediated migration, invasion, and proliferation in NSCLC cells.

Discussion
==========

TRIM67 is a protein that belongs to TRIM family and is localized to the cytoplasm and nucleus. Here, we demonstrated that TRIM67 is expressed in NSCLC and multiple lung cancer cell lines.

In this study, we showed that the expression of TRIM67 was associated with a range of clinicopathological features, such as tumor size, differentiation, lymph node metastasis, p-TNM staging, and prognosis. We also demonstrated that TRIM67 promotes the proliferation, migration, invasion and EMT of NSCLC cells through the Notch pathway and the expression of downstream proteins such as RhoA, RhoC, MMP-9, P21, c-myc, and EMT-related markers [@B17], [@B20], [@B21], thereby influencing the malignant behavior of tumor cells. However, the mechanisms involved in these functions are unclear, and further studies are needed.

The role of the Notch pathway in cancers has been determined according to the effect of Notch pathway on cell proliferation, migration, and invasion [@B22]-[@B26]. In the present study, we demonstrated that TRIM67 overexpression can upregulate Notch1, Jagged1, and NICD. NICD translocates to the nucleus, where it binds to several transcription factors and regulates the expression of target genes. The γ-secretase inhibitor DAPT blocks the Notch pathway by reducing the formation of NICD [@B27]. When we added DAPT, the effects of TRIM67 on NSCLC functions were reversed, which confirmed that TRIM67 functions through the regulation of Notch signaling.

However, in this study, we did not confirm how TRIM67 acts on the Notch pathway. TRIM67 is an E3 ubiquitin ligase, so we speculate that this pathway is activated by ubiquitination of Notch pathway-inhibiting proteins. Even if this is true, it is still unclear which domain and binding site of TRIM67 are involved in this process, and thus further studies are needed.

In conclusion, our study demonstrated that TRIM67 plays a significant role in NSCLC via the Notch pathway, suggesting that TRIM67 might be a candidate prognostic biomarker and possible therapeutic target for NSCLC. Even though further studies are needed to determine the functions of TRIM67 in these biological processes, our results offer significant views and reflections about the functions and mechanisms of TRIM67 in tumorigenesis.
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![Expression of TRIM67 in non-small cell lung cancer (NSCLC) is associated with poor clinical prognosis. **a** TRIM67 protein levels were analyzed by immunohistochemistry in (i) alveolar cells, (ii) normal bronchial epithelial cells, (iii) well-differentiated squamous cell carcinoma, (iv) well-differentiated adenocarcinoma, (v) poorly differentiated squamous cell carcinoma, (vi) poorly differentiated adenocarcinoma. **b** Survival of NSCLC patients with high and low TRIM67 expression based on Kaplan-Meier curves. Hazard ratio (HR) and *P* value are indicated. **c** Immunofluorescence assays were performed to detect TRIM67 localization in human normal bronchial epithelial and NSCLC cell lines. TRIM67 was localized to the cytoplasm and nucleus. **d** TRIM67 levels in HBE cells and six NSCLC cell lines according to western blot analysis. Relative quantification analysis was based on gray scale values.](jcav11p1240g001){#F1}

![TRIM67 protein levels are positively correlated with non-small cell lung cancer (NSCLC) migration and invasion. **a** Transwell assays were performed to assess cell migration and invasion after TRIM67 overexpression and downregulation. TRIM67 overexpression in A549 and H1299 cells enhanced cell migration and invasion, whereas TRIM67 knockdown inhibited these processes. \*P \< 0.05; \*\*P \< 0.01.**b, c** Effects of TRIM67 levels on the expression of proteins associated with cell migration and invasion in A549 and H1299 cells. Relative quantification analysis was based on gray scale values. \*P \< 0.05; \*\*P \< 0.01.](jcav11p1240g002){#F2}

![TRIM67 protein levels are positively correlated with non-small cell lung cancer (NSCLC) cell proliferation. **a** Colony formation assays were performed to assess cell proliferation after TRIM67 overexpression and downregulation. TRIM67 overexpression in A549 and H1299 cells enhanced cell proliferation, whereas TRIM67 knockdown inhibited cell proliferation. \*P \< 0.05; \*\*P \< 0.01. **b, c** MTT assays were performed to confirm that TRIM67 overexpression enhances cell proliferation and that TRIM67 knockdown inhibits this process. \*P \< 0.05; \*\*P \< 0.01. **d, e** The effects of TRIM67 upregulation or downregulation on the expression of proteins associated with cell proliferation in A549 and H1299 cells. Relative quantification analysis was based on gray scale values. \*P \< 0.05; \*\*P \< 0.01.](jcav11p1240g003){#F3}

![Effects of TRIM67 levels on the expression of epithelial-mesenchymal transition (EMT)-related proteins. **a** A549 and**b** H1299 cells were transfected with expression or shRNA vectors. Relative quantification analysis was based on gray scale values. \*P \< 0.05; \*\*P \< 0.01.](jcav11p1240g004){#F4}

![TRIM67 modulates Notch signaling to regulate cell migration and invasion in non-small cell lung cancer. **a**, **b** Changes in the expression of Notch-related proteins in **a** A549 and **b** H1299 cells. Relative quantification analysis was based on gray scale values. \*P \< 0.05; \*\*P \< 0.01. **c** Changes in the migration and invasion capacity of A549 and H1299 cells in the presence or absence of treatment with the Notch inhibitor DAPT and transfection with p-TRIM67. \*P \< 0.05; \*\*P \< 0.01.](jcav11p1240g005){#F5}

![Notch signaling mediates the effects of TRIM67 on proliferation and epithelial-mesenchymal transition (EMT). **a** Changes in the proliferation activity of A549 and H1299 cells in the presence or absence of the Notch inhibitor DAPT after transfection with p-TRIM67. \*P \< 0.05; \*\*P \< 0.01. **b, c** Effect of TRIM67 in the presence or absence of Notch inhibition on protein expression in non-small cell lung cancer (NSCLC) cells. **b** A549 and **c** H1299 cells transfected with p-TRIM67 were treated with or without the Notch inhibitor DAPT and analyzed by western blotting for the expression of proteins involved in cell migration, invasion, proliferation, and EMT. Relative quantification analysis was based on gray scale values. \**P*\< 0.05; \*\**P*\< 0.01.](jcav11p1240g006){#F6}

###### 

List of antibodies used for western blotting in the study.

  --------------------------------------------------------------------------------------
  Antibody name   Source                           Catalog number   Host      Dilution
  --------------- -------------------------------- ---------------- --------- ----------
  TRIM67\         Sigma-Aldrich\                   HPA034776\       Rabbit\   1:50\
  TRIM67          Sigma-Aldrich                    SAB2103188       Rabbit    1:100

  GAPDH           Beyotime                         AF0006           Mouse     1:1000

  RhoA\           Cell Signaling Technology Inc\   2117\            Rabbit\   1:500\
  RhoC            Cell Signaling Technology Inc    3430             Rabbit    1:500

  MMP9            Cell Signaling Technology Inc    13667            Rabbit    1:500

  P21             Cell Signaling Technology Inc    2947             Rabbit    1:1000

  c-myc           Cell Signaling Technology Inc    13987            Rabbit    1:1000

  E-Cadherin      Proteintech                      20874            Rabbit    1:500

  N-Cadherin      Proteintech                      22018            Rabbit    1:500

  Vimentin\       Proteintech\                     10366\           Rabbit\   1:500\
  Snail\          Cell Signaling Technology Inc\   3879\            Rabbit\   1:500\
  Slug\           Cell Signaling Technology Inc\   9585\            Rabbit\   1:500\
  Jagged1\        Cell Signaling Technology Inc\   2620\            Rabbit\   1:500\
  Notch1\         Cell Signaling Technology Inc\   3608\            Rabbit\   1:500\
  NICD            Wanlei Bio                       WL03097a         Rabbit    1:500

  HA              TransGen Biotech                 HT301            Mouse     1:1000
  --------------------------------------------------------------------------------------

###### 

Association between TRIM67 expression and clinicopathological characteristics of non-small cell lung cancer patients.

  Clinicopathological characteristics   Total N   *TRIM67*-positive   *TRIM67*-negative   *P* value
  ------------------------------------- --------- ------------------- ------------------- -----------
  Age (years)                                                                             
  ≤ 60                                  148       81                  67                  
  \> 60                                 106       70                  36                  0.424
  Sex                                                                                     
  Male                                  143       78                  65                  
  Female                                111       44                  67                  0.328
  Histological type                                                                       
  Squamous cell carcinoma               106       60                  46                  
  Adenocarcinoma                        148       88                  60                  0.514
  Differentiation                                                                         
  Well-moderate                         127       44                  83                  
  Poor                                  127       74                  53                  \< 0.001
  Tumor size (cm)                                                                         
  ≤ 5                                   224       98                  126                 
  \> 5                                  30        20                  10                  0.018
  Lymph node metastasis                                                                   
  Negative                              150       52                  98                  
  Positive                              104       66                  38                  \< 0.001
  TNM stage                                                                               
  I                                     148       50                  98                  
  II-III                                106       67                  39                  \< 0.001
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